Affiliation:
1. Anne C. Wheeler, Genomics, Ethics, and Translational Research Program, RTI International
Abstract
Abstract
Neurogenetic conditions (NGC; e.g., fragile X, Angelman, Prader-Willi syndromes) represent the cause for intellectual or developmental disabilities in up to 60% of cases. With expanded diagnostic options and an increasing focus on the development of gene therapies comes the potential of improved quality of life for individuals with NGCs and their families. However, these emerging initiatives also bring new challenges and considerations for NGC researchers and clinicians, including considerations for supporting caregivers and assuring outcome measures for clinical trials adequately reflect the lived experiences of people with NGCs. This paper summarizes the advances and current and future challenges of research and clinical service provision for people with NGCs and their caregivers.
Publisher
American Association on Intellectual and Developmental Disabilities (AAIDD)
Reference24 articles.
1. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges;Adachi,;International journal of environmental research and public health,(2023)
2. Preparing newborn screening for the future: A collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system;Andrews,;BMC pediatrics,(2022)
3. A window of opportunity for newborn screening;Bailey;Molecular Diagnosis & Therapy,(2022)
4. Supporting family adaptation to presymptomatic and “untreatable” conditions in an era of expanded newborn screening;Bailey;Journal of Pediatric Psychology,(2009)
5. Early Check: Translational science at the intersection of public health and newborn screening;Bailey,;BMC Pediatrics,(2019)